Adagrasib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 3, p. 275, doi. 10.1007/s40265-023-01839-y
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 3
Results: 6
1
2
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
- Published in:
- Drugs, 2023, v. 83, n. 3, p. 217, doi. 10.1007/s40265-023-01835-2
- By:
- Publication type:
- Article
3
Mirvetuximab Soravtansine: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 3, p. 265, doi. 10.1007/s40265-023-01834-3
- By:
- Publication type:
- Article
4
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?
- Published in:
- Drugs, 2023, v. 83, n. 3, p. 195, doi. 10.1007/s40265-022-01833-w
- By:
- Publication type:
- Article
5
Diagnosis and Treatment of AL Amyloidosis.
- Published in:
- Drugs, 2023, v. 83, n. 3, p. 203, doi. 10.1007/s40265-022-01830-z
- By:
- Publication type:
- Article
6
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.
- Published in:
- Drugs, 2023, v. 83, n. 3, p. 249, doi. 10.1007/s40265-022-01822-z
- By:
- Publication type:
- Article